EN | RU
EN | RU

Help Support

Back

Can body weight impact response to nasal glucocorticoids in allergic rhinitis?

Allergic rhinitis Allergic rhinitis
Allergic rhinitis Allergic rhinitis

What's new?

In individuals with allergic rhinitis undergoing treatment with nasal corticosteroids, obesity does not impact nasal symptoms and physiology, but it hampers anti-inflammatory response.

As per the findings of a recent study, obesity does not appear to influence nasal physiology and symptoms among allergic rhinitis patients undergoing treatment with nasal corticosteroids. Nonetheless, there was an observable impact on the anti-inflammatory response, as obese individuals demonstrated diminished responsiveness in comparison to those with a normal weight. Researchers sought to assess how body weight influences the effectiveness of treating allergic rhinitis with nasal corticosteroids.

A comparison was made between two groups of subjects suffering from allergic rhinitis: one comprising individuals with obesity and the other consisting of those with normal weight. Assessments, including Nasal Obstruction and Septoplasty Effectiveness (NOSE-5) questionnaires, 22-item Sinonasal Outcome Test (SNOT22), visual analogue scales (VAS), quality of life, peak nasal inspiratory flow, nasal endoscopy and the measurement of nasal cytokines (Interleukin [IL-10], IL-6, IL-5, IL-4, tumor necrosis factor [TNF]-ᾳ, and interferon [INF]-γ) via nasal brushing, were conducted before and after intervention with 400 mcg/day nasal Beclomethasone.

No distinctions were observed between the groups concerning NOSE-5 questionnaires, SNOT22, VAS, peak nasal inspiratory flow, nasal endoscopy, or cytokines (IL-10, IL-6, IL-5, IL-4, TNF-ᾳ, and INF-γ) prior to the initiation of nasal corticosteroid treatment. Both groups exhibited enhancements in VAS, SNOT-22, and NOSE-5 scores, along with an elevation in peak nasal inspiratory volumes following the intervention. Following the treatment, there was a rise in IL-5 and INF-γ within the eutrophic group.

When contrasting the alterations in cytokine levels pre and post treatment across groups, it was evident that IL-10 exhibited altered behavior depending on the weight of the individuals. Nasal symptoms and physiology did not appear to be influenced by obesity, and obese individuals exhibited a comparable clinical response to nasal corticosteroid treatment as normal-weight patients. Nevertheless, obese patients demonstrated a compromised anti-inflammatory response during the course of nasal corticosteroid treatment.

Source:

Indian Journal of Otolaryngology and Head & Neck Surgery

Article:

Effect of Body Weight on Response to Nasal Glucocorticoid Treatment in Allergic Rhinitis

Authors:

Marina de Sá Pittondo et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru ua
Try: